国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Business / Companies

China accuses former GSK head of bribing doctors

(Xinhua) Updated: 2014-05-14 15:39

According to police, Reilly and his colleagues disguised illegal revenue in the Chinese market by forging transactions between GSK China and several foreign arms of GSK, making the revenue look like funds used to purchase raw materials in China. They made every effort to cover up the illegal practice during regular checks by regulatory authorities. In terms of sales of prescription drugs and vaccines, police found that all pharmaceutical factories and departments of GSK China nationwide had been involved in commercial bribery.

Last July, police detained four senior executives of GSK China on suspicion of commercial bribery. Reilly was not among them.

Drug price inflation 

The investigation exposed how GSK inflated drug prices to accommodate bribery expenses and high profits. According to the police, in the most extreme case, the price on the Chinese market was seven times that in other countries.

A company document obtained by Xinhua showed that a box of Heptodin is priced 142 yuan by GSK China but only 18 yuan in South Korea, about 26 yuan in Canada and 30 yuan in the United Kingdom.

Police statement said GSK China intentionally inflated prices on the Chinese market by making false declarations to Chinese customs. Chen Hongbo, former vice president of GSK China, told the police that the price was further inflated when drugs were imported into China and packed in GSK's factories here. When a drug was sold to China, the factory price has already included profits and commissions. To avoid paying taxes in China, the company would divide production among GSK branches in different countries and pack them in China as the last step, according to Chen.

The actual cost of a box of Heptodin is 15.7 yuan. It is declared as 73 yuan at customs and priced at 142 yuan as factory price. The highest retail price is 207 yuan in China.

Through such practices, the company disguised profits as costs. Although revenue soared from 2009 to 2012, booked profits remained small. In 2012, it recorded a loss of 188 million yuan on a main business revenue of 6.98 billion yuan.

To sell such expensive drugs, high kickbacks to hospitals and doctors became a necessity.

GSK revamps sales reps' compensation

GSK denies it is considering leaving China

GSK revamps sales reps' compensation

Police reveals more about GSK China's violations

China accuses former GSK head of bribing doctors

China accuses former GSK head of bribing doctors

GSK's China sales may be down 30% on bribery scandal

Police reveals more about GSK China's violations 

Previous Page 1 2 3 Next Page

Hot Topics

Editor's Picks
...
...
扬中市| 拜城县| 抚宁县| 桃园县| 昌宁县| 团风县| 乌海市| 九寨沟县| 内江市| 遂川县| 定兴县| 巴塘县| 青岛市| 南投市| 舞钢市| 基隆市| 庐江县| 噶尔县| 翁牛特旗| 通江县| 黑山县| 安阳市| 砚山县| 冀州市| 沂水县| 南江县| 温宿县| 万荣县| 宜丰县| 平果县| 曲松县| 门源| 牡丹江市| 宜城市| 盐边县| 祁连县| 北辰区| 定兴县| 九台市| 五大连池市| 津南区|